Coherus BioSciences, Inc.
CHRS
$0.7818
-$0.0349-4.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -40.84% | -5.09% | 10.67% | 137.58% | 101.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -40.84% | -5.09% | 10.67% | 137.58% | 101.81% |
| Cost of Revenue | -59.96% | -36.58% | 14.17% | 104.97% | 495.46% |
| Gross Profit | 191.59% | 19.51% | 8.10% | 172.95% | -77.67% |
| SG&A Expenses | -27.31% | -23.85% | -22.10% | 0.83% | -11.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.11% | -25.79% | -8.33% | 12.85% | 59.98% |
| Operating Income | 43.94% | 78.28% | 40.63% | 50.23% | -23.13% |
| Income Before Tax | 36.35% | 73.14% | 69.86% | 235.85% | -35.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.35% | 72.88% | 69.86% | 235.85% | -35.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.35% | 72.88% | 69.86% | 235.85% | -35.30% |
| EBIT | 43.94% | 78.28% | 40.63% | 50.23% | -23.13% |
| EBITDA | 44.64% | 83.03% | 42.60% | 51.87% | -23.59% |
| EPS Basic | 38.52% | 77.00% | 77.10% | 195.51% | 5.40% |
| Normalized Basic EPS | -187.35% | 75.64% | 99.48% | 60.84% | 11.93% |
| EPS Diluted | 34.87% | 77.24% | 77.10% | 186.35% | 4.73% |
| Normalized Diluted EPS | -187.35% | 75.64% | 99.48% | 64.83% | 11.93% |
| Average Basic Shares Outstanding | 3.52% | 17.88% | 31.57% | 42.24% | 43.02% |
| Average Diluted Shares Outstanding | 3.52% | 17.88% | 31.57% | 58.36% | 43.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
